DfuseRx product discovery technology
Intensity Therapeutics’ DfuseRx technology enables direct injection of drug compounds into solid tumors with high absorption.
intensitytherapeutics.comCrawled Nov 19, 2026
Intensity Therapeutics’ DfuseRx technology enables direct injection of drug compounds into solid tumors with high absorption.
The INVINCIBLE-3 study evaluates INT230-6 (intratumoral administration) against the U.S. standard of care for soft tissue sarcomas.
Intensity Therapeutics conducts clinical trials to test interventions like drugs, devices, or behavioral changes in cancer research.
Intensity has been granted three US patents and has 13 foreign patents with protection in 37 countries. Additionally, Intensity has been granted patents in: Australia Austria Belgium Brazil Canada China Cypress Czech Republic Denmark Finland France Germany Greece Italy Ireland Japan Korea (South) Luxembourg Macau Macedonia Malta Mexico Monaco Netherlands Norway Poland Portugal Romania Russia ... Read more
INT230-6 combines a cell penetration enhancer (SHAO), cisplatin, and vinblastine to target cancer cells.
INT230-6 demonstrates efficacy in killing tumors through localized cell death in both animal and human trials.
Intensity Therapeutics is approved as a ‘Qualified Connecticut Business’ by Connecticut Innovations.
Intensity Therapeutics collaborates with the National Cancer Institute’s laboratory led by Jay Berzofsky, MD, Ph.D., for material exchange.
Intensity Therapeutics, Inc. (private) announced the Company has raised over $225,000 in a preseed funding. The source of capital was from Angel Investors. The funding will be used for research and development of the Company’s novel products.
Lewis H. Bender, President and CEO of Intensity Therapeutics, will present at the 5th Annual Biotech Showcase & Investor Conference in San Francisco.
Lewis H. Bender, President and CEO of Intensity Therapeutics, will present at the Life Sciences Venture Summit in New York City.
Lewis H. Bender, President and CEO of Intensity Therapeutics, will present at the Annual New York Biotech Conference in New York City.
Lewis H. Bender, founder and CEO of Intensity Therapeutics, has over 28 years of biopharmaceutical leadership experience.
Intensity Therapeutics mourns the loss of longtime toxicology advisor Dr. Chris J. Viau, who passed away in December 2021.
Intensity Therapeutics develops cancer drugs designed to shrink tumors with minimal side effects and train the immune system to fight cancer.
Intensity Therapeutics provides contact information for inquiries about its technology and products, including headquarters and investor/media contacts.
Intensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors AND induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and metastatic disease.
Intensity Therapeutics develops INT230-6, an investigational drug for treating solid tumor cancers via intratumoral injection.